A booster dose of Pfizer/BioNTech's Covid-19 vaccine showed high efficacy against the virus, including the Delta variant, in a phase III trial, it was reported yesterday. The study was conducted on a sample of 10,000 participants over the age of 16, and the effectiveness was 95.6 per cent.more